Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. by Besselink, MG, van Santvoort, H, Renooij, W, de Smet, M, Boermeester, M, Fischer, K, Timmerman, H, Ahmed Ali, U, Cirkel, G, Bollen, T, van Ramshorst, B, Schaapherder, A, Witteman, B, Ploeg, R, van Goor, H, van Laarhoven, C, Tan, A, Brink, M, van der Harst, E, Wahab, P, Eijck, v, Dejong, C, van Erpecum, K, Akkermans, L, Gooszen, H

“… OBJECTIVES: To determine the relation between intestinal barrier dysfunction, bacterial translocation, and clinical outcome in patients with predicted severe acute pancreatitis and the influence of probiotics on these processes. …”

Intestinal barrier dysfunction in a randomised placebo-controlled trial of probiotic prophylaxis in acute pancreatitis by Besselink, MG, van Santvoort, H, Boermeester, M, Fischer, K, Renooij, W, de Smet, M, Ali, U, Cirkel, G, Bollen, T, van Ramshorst, B, Weusten, B, Schaapherder, A, Witteman, B, Ploeg, R, van Goor, H, van Laarhoven, C, Tan, A, Brink, M, Van der Harst, E, Wahab, P, Eijck, v, Dejong, C, van Erpecum, K, Akkermans, L, Gooszen, H

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. by Besselink, MG, van Santvoort, H, Buskens, E, Boermeester, M, van Goor, H, Timmerman, H, Nieuwenhuijs, V, Bollen, T, van Ramshorst, B, Witteman, B, Rosman, C, Ploeg, R, Brink, M, Schaapherder, A, Dejong, C, Wahab, P, van Laarhoven, C, van der Harst, E, Eijck, v, Cuesta, M, Akkermans, L, Gooszen, H

“… BACKGROUND: Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. …”

Probiotic prophylaxis In predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial by Besselink, MG, van Santvoort, H, Buskens, E, Boermeester, M, van Goor, H, Timmerman, H, Nieuwenhuijs, V, Bollen, T, van Ramshorst, B, Witteman, B, Rosman, C, Ploeg, R, Brink, M, Schaapherder, A, Dejong, C, Wahab, P, van Laarhoven, C, van der Harst, E, Eijck, v, Cuesta, M, Akkermans, L, Gooszen, H, Grp, D

[Probiotic prophylaxis in patients with predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial]. by Besselink, MG, van Santvoort, H, Buskens, E, Boermeester, M, van Goor, H, Timmerman, H, Nieuwenhuijs, V, Bollen, T, van Ramshorst, B, Witteman, B, Rosman, C, Ploeg, R, Brink, M, Schaapherder, A, Dejong, C, Wahab, P, van Laarhoven, C, van der Harst, E, Eijck, v, Cuesta, M, Akkermans, L, Gooszen, H

“… OBJECTIVE: To evaluate whether enteral prophylaxis with probiotics in patients with predicted severe acute pancreatitis prevents infectious complications. DESIGN: Multicentre, randomised, double-blind, placebo-controlled trial. …”

Probiotic prophylaxis in patients with predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial by Besselink, M, Van Santvoort, H, Buskens, E, Boermeester, M, Van Goor, H, Timmerman, H, Nieuwenhuijs, V, Bollen, T, Van Ramshorst, B, Witteman, B, Rosman, C, Ploeg, R, Brink, M, Schaapherder, A, Dejong, C, Wahab, P, Van Laarhoven, C, Van Der Harst, E, Van Eijck, G, Cuesta, M, Akkermans, L, Gooszen, H

“…To evaluate whether enteral prophylaxis with probiotics in patients with predicted severe acute pancreatitis prevents infectious complications. Design. …”

Early endoscopic retrograde cholangiopancreatography in predicted severe acute biliary pancreatitis: a prospective multicenter study. by van Santvoort, H, Besselink, MG, de Vries, A, Boermeester, M, Fischer, K, Bollen, T, Cirkel, G, Schaapherder, A, Nieuwenhuijs, V, van Goor, H, Dejong, C, Eijck, v, Witteman, B, Weusten, B, van Laarhoven, C, Wahab, P, Tan, A, Schwartz, M, van der Harst, E, Cuesta, M, Siersema, P, Gooszen, H, van Erpecum, K

“…One hundred fifty-three patients with predicted severe ABP without cholangitis enrolled in a randomized multicenter trial on probiotic prophylaxis in acute pancreatitis were prospectively followed. Conservative treatment or ERCP within 72 hours after symptom onset (at discretion of the treating physician) were compared for complications and mortality. …”